1Gambort SR, Sehultz BM, Handy RC et al. Osteoporosis:clinical features, prevention and treatment. Endoerionol Metab Clin North Am. 1995;24:317～371
2Kanis JS. Melton LJ. Christiansen C et al. The diagnosis of osteoporosis. J Bone Miner Res, 1994;9:1137～1141
3WHO Technical Report Series 843: Assessment of fracture and its application to screening for postmenopausal osteoporosis.Genera:World Health Ognization,1994
4Taxel P. Osteoporosis: detection, prevention and treatment in primary care. Geriatrics, 1998;53:22～40
5Ross PD. Risk factors for osteoporotic fracture. Endocrinol Metab Clin North Am,1998;27:289～302
6Dawson-Hughes B. Hams SS. Krall EA et al. Effect of calcium and vitmin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med,1997;337: 670～676
7Lips P. Graafmans WC. Ooms ME et al. Vitmin D supplem entation and fracture incidence in elderly person:a randomized, placebocontrolled clinical trial. Ann Intern Med, 1996;124:400～406
8Reid IR. The roles of calcium and vitamin D in the prevention of osteoporosis. Endocrinol Metab Clin North Am, 1998;27: 389～398
9Effects of bormone therapy on bone mineral density:results from the postmenopausal estrogen/progestin intervention (PEPI) trial: the Writng Group for the PEPI. JAMA, 1996;276:1389～1396
10Pots Nielsen S, Barnholdt O, Hermansen F et al. Mangnitude and pattern of skeletal response to long-term continous and cyclic sequential ostrogen/progestin. Br J Obster Gynaecol, 1994;101:319～324
1Rossouw JE, Anderson GL, Prentice RL, et al. Risk and benefits of estrogen plus progestin in healty postmenopausal women:principal resulesf rom the women's health initiative randomized controlled trial [ J ]. JAMA ,2002,288(3) :321-333.
2Cummings SR, Echkert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women:results form the MORE randomized trial[J] .JAMA, 1999,281(23) :2189-2197.
3Black LJ,Jones CD, Falcone JF. Antagonism of estrogen action with a new benzothiophene derived antiestrogen [ J ]. Life Sci, 1983,32 ( 9 ) :1031-1036.
4Evans G, Bryant H, Sato M, et al. Raloxifene is a tissue-specific estrogen agonist[ J]. J Bone Miner Res, 1993,8[ Suppl 1 ] : S134.
5Sato M, Glasebrook AL, Bryant HU. Raloxifene : a selective estrogen receptor modulator[ J ]. J Bone Miner Metab, 1994,12 [ Suppl 2 ] : S9-S20.
6Evans GI, Bryant HU, Magee DE, et al. Raloxifene inhibits bone turnover and prevents further cancellous bone loss in adult ovariectomized rats with established osteopenia [ J]. Endocrinology, 1996, 137 (10) :4139-4144.
7Black LJ,Sato M, Rowley ER, et al. Raloxifene( LY139481 HCl) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats [ J ]. J Clin Invest, 1994,93 ( 1 ) :63-69.
8Bryant HU ,Turner CH, Frolik Cal., et al. Long term effects of raloxifene on bone, cholesterol and uterus in ovariectomized rats[ J]. Bone, 1995,16[ Suppl] : 116S.
9Turner CH, Sato M, Bryant HU. The effects of long-term raloxifene treatment on bone strength in ovaricetomized rats[J]. J Bone Miner Res, 199g ,9[ Suppl ] : S325.
10Turner CH, Sato M, Bryant HU. Raloxifene preserves bone strength and bone mass in ovaricetomized rats [ J ] . Endocrinology, 1994, 135 ( 5 ) :2001-2005.
